Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antisense oligonucleotide therapies

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lipigon

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition March 23, 2020

            Details:

            Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.